111 related articles for article (PubMed ID: 29970342)
1. Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.
Lee YC; Hsieh CC; Lee YL; Li CY
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):558-568. PubMed ID: 29970342
[TBL] [Abstract][Full Text] [Related]
2. Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?
Salit RB; Deeg HJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):649-658. PubMed ID: 29128551
[TBL] [Abstract][Full Text] [Related]
3. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
5. Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study.
Luque Paz D; Riou J; Verger E; Cassinat B; Chauveau A; Ianotto JC; Dupriez B; Boyer F; Renard M; Mansier O; Murati A; Rey J; Etienne G; Mansat-De Mas V; Tavitian S; Nibourel O; Girault S; Le Bris Y; Girodon F; Ranta D; Chomel JC; Cony-Makhoul P; Sujobert P; Robles M; Ben Abdelali R; Kosmider O; Cottin L; Roy L; Sloma I; Vacheret F; Wemeau M; Mossuz P; Slama B; Cussac V; Denis G; Walter-Petrich A; Burroni B; Jézéquel N; Giraudier S; Lippert E; Socié G; Kiladjian JJ; Ugo V
Blood Adv; 2021 Mar; 5(5):1442-1451. PubMed ID: 33666653
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis.
Wang Z; Liu W; Wang M; Li Y; Wang X; Yang E; Ming J; Quan R; Hu X
Ann Hematol; 2021 Feb; 100(2):465-479. PubMed ID: 33386934
[TBL] [Abstract][Full Text] [Related]
7. Clinical impacts of the mutational spectrum in Japanese patients with primary myelofibrosis.
Morishita S; Ochiai T; Misawa K; Osaga S; Inano T; Fukuda Y; Edahiro Y; Ohsaka A; Araki M; Komatsu N
Int J Hematol; 2021 Apr; 113(4):500-507. PubMed ID: 33389584
[TBL] [Abstract][Full Text] [Related]
8. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.
Lasho TL; Jimma T; Finke CM; Patnaik M; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Blood; 2012 Nov; 120(20):4168-71. PubMed ID: 22968464
[TBL] [Abstract][Full Text] [Related]
9. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract][Full Text] [Related]
10. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.
Brecqueville M; Rey J; Devillier R; Guille A; Gillet R; Adélaide J; Gelsi-Boyer V; Arnoulet C; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D; Murati A
Haematologica; 2014 Jan; 99(1):37-45. PubMed ID: 23996481
[TBL] [Abstract][Full Text] [Related]
11. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P; Lasho TL; Rotunno G; Mudireddy M; Mannarelli C; Nicolosi M; Pacilli A; Pardanani A; Rumi E; Rosti V; Hanson CA; Mannelli F; Ketterling RP; Gangat N; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM; Tefferi A
J Clin Oncol; 2018 Feb; 36(4):310-318. PubMed ID: 29226763
[TBL] [Abstract][Full Text] [Related]
12. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
[TBL] [Abstract][Full Text] [Related]
13. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular genetic characterization of myelofibrosis.
Hobbs GS; Rampal RK
Curr Opin Hematol; 2015 Mar; 22(2):177-83. PubMed ID: 25635755
[TBL] [Abstract][Full Text] [Related]
15. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Tamari R; Rapaport F; Zhang N; McNamara C; Kuykendall A; Sallman DA; Komrokji R; Arruda A; Najfeld V; Sandy L; Medina J; Litvin R; Famulare CA; Patel MA; Maloy M; Castro-Malaspina H; Giralt SA; Weinberg RS; Mascarenhas JO; Mesa R; Rondelli D; Dueck AC; Levine RL; Gupta V; Hoffman R; Rampal RK
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1142-1151. PubMed ID: 30625392
[TBL] [Abstract][Full Text] [Related]
16. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
Lin Y; Zheng Y; Wang ZC; Wang SY
Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
[TBL] [Abstract][Full Text] [Related]
18. Targeted deep sequencing in primary myelofibrosis.
Tefferi A; Lasho TL; Finke CM; Elala Y; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Adv; 2016 Dec; 1(2):105-111. PubMed ID: 29296803
[TBL] [Abstract][Full Text] [Related]
19. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of SRSF2 mutations in patients with de novo myelodysplastic syndromes: A meta-analysis.
Zheng X; Zhan Z; Naren D; Li J; Yan T; Gong Y
PLoS One; 2017; 12(9):e0185053. PubMed ID: 28953917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
